Market Access News | pharmaphorum

News

Verona’s first-in-class COPD drug ‘could transform market’

Verona Pharma has claimed FDA approval for its chronic obstructive pulmonary disease (COPD) drug ensifentrine, which has been tipped as a future blockbuster.

News

Wales and NI follow England in backing Vertex CF therapies

Three of the four UK nations have agreed a long-term deal with Vertex Pharma for reimbursement of its cystic fibrosis therapies, ensuring permanent access to the drugs for eligible patients

News

Daiichi Sankyo’s Ezharmia cleared in Japan for rare lymphoma

Daiichi Sankyo has a second approval in Japan for Ezharmia, its first-in-class dual EZH1 and EZH2 inhibitor, as a treatment for relapsed or refractory peripheral T-cell lymphoma (PTCL).

News

BMS gets FDA approval for Krazati in colorectal cancer

Bristol-Myers Squibb’s KRAS inhibitor Krazati has been approved for a second indication, colorectal cancer (CRC), which could inject some much-needed sales growth into the product.

News

FDA clears Argenx’ Vyvgart Hytrulo for rare disease CIDP

Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug t

News

Sarepta bags key expansion to DMD gene therapy label in US

Sarepta’s gene therapy for Duchenne muscular dystrophy (DMD) will be an option for many more patients in the US after the FDA expanded the breadth of its approved labelling.

Verona’s first-in-class COPD drug ‘could transform market’

Wales and NI follow England in backing Vertex CF therapies

Daiichi Sankyo’s Ezharmia cleared in Japan for rare lymphoma

BMS gets FDA approval for Krazati in colorectal cancer

FDA clears Argenx’ Vyvgart Hytrulo for rare disease CIDP

Sarepta bags key expansion to DMD gene therapy label in US

Madrigal builds in MASH with $4.4bn+ Ribo alliance

How to meet your physicians where they are online

News

Editor's Picks